10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
JOHNSON & JOHNSON | |||
Ticker: JNJ Fiscal Year: 2014 | |||
Consolidated Statements of Earnings | |||
Period Ending Dec 28, 2014 10-K (Filed: Feb 24, 2015) | |||
| (In Millions, except shares in Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 28, 2014 | Dec 29, 2013 | Dec 30, 2012 | |
| Sales to customers | $ 74,331 | 71,312 | 67,224 |
| Cost of products sold | 22,746 | 22,342 | 21,658 |
| Gross profit | 51,585 | 48,970 | 45,566 |
| Selling, marketing and administrative expenses | 21,954 | 21,830 | 20,869 |
| Research and development expense | 8,494 | 8,183 | 7,665 |
| In-process research and development | 178 | 580 | 1,163 |
| Interest income | (67) | (74) | (64) |
| Interest expense, net of portion capitalized (Note 4) | 533 | 482 | 532 |
| Other (income) expense, net | (70) | 2,498 | 1,626 |
| Earnings before provision for taxes on income | 20,563 | 15,471 [1] | 13,775 |
| Provision for taxes on income (Note 8) | 4,240 | 1,640 | 3,261 |
| Net earnings | 16,323 | 13,831 | 10,514 |
| Add: Net loss attributable to noncontrolling interest | 0 | 0 | 339 |
| Net earnings attributable to Johnson & Johnson | 16,323 | 13,831 | 10,853 |
| Net earnings per share attributable to Johnson & Johnson (Notes 1 and 15) | |||
| Basic | 5.80 | 4.92 | 3.94 |
| Diluted | 5.70 | 4.81 | 3.86 |
| Cash dividends per share | 2.76 | 2.59 | 2.40 |
| Average shares outstanding (Notes 1 and 15) | |||
| Basic | 2,815,200 | 2,809,200 | 2,753,300 |
| Diluted | 2,863,900 | 2,877,000 | 2,812,600 |
| [1] Includes $2,276 million of net litigation expense comprised of $1,975 million and $301 million in the Medical Devices and Pharmaceutical segments, respectively. Includes $683 million of Synthes integration/transaction costs in the Medical Devices segment. Includes $580 million of in-process research and development expense, comprised of $514 million and $66 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment also includes $251 million expense for the cost as | |||
| External Links | |
| JOHNSON & JOHNSON (JNJ) Fiscal Year 2014 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |